Description
The ProClarix Prostate Cancer Test is a next generation blood test from UK based Cambridge Clinical Laboratories to diagnose prostate cancer without the need to have an invasive biopsy. Ideal for those with a Prostate Specific Antigen (PSA) of 2-10 ng/ml and available at our Cardiff Clinic at no additional charge or anywhere in the UK for an additional £85.
Click here to download CCL Proclarix Bladder Cancer Patient Flyer
Click here to learn more about prostate cancer and screening for prostate cancer.
FAQs
What does Proclarix measure?
Proclarix measures PSA (Prostate Specific Antigen) and two protein biomarkers in the blood (THBS1 and CTSD). This information goes into an algorithm alongside your age to get your risk score. THBS1 and CTSD are proteins which are present in the blood at different levels when there is a tumour, so can indicate the presence of cancer even if your PSA is normal.
How can I get a Proclarix test?
Contact our office team on 0345 2303386 and we will discuss the test and arrange it for you if you wish to go ahead.
Do I have to pay for Proclarix?
Unfortunately, Proclarix is not yet covered by the NHS. You will need to pay for the Proclarix test, and you will need to pay a phlebotomy fee to have your bloods taken unless you have the sample taken in our Cardiff Clinic.
What do the results look like?
Proclarix gives you a risk score, as shown below, where 10% is the recommended cut-off. If your score is green, you are low-risk which helps give peace-of-mind that you are unlikely to need further investigation at this point. If your score is red, you should have further investigation, which will be an MRI scan or a biopsy if you’ve already had an MRI.
To view a sample report, please visit www.camclinlabs.co.uk/proclarix
How will I receive my results?
The results will be sent to the doctor/hospital that requested the Proclarix test for you. They will arrange an appointment with you to discuss the results.
How accurate is the test?
The test has a 95% Negative Predictive Value, meaning that 1 out of 20 men with a low-risk score will have prostate cancer. In comparison, 1 in 7 men with a normal PSA will have prostate cancer.
How long has the test been around?
Proclarix was developed by Proteomedix, a Swiss healthcare diagnostics company. Proclarix was launched in Europe in 2020 after many years of research. It is CE-Marked and included in the EAU Guidelines. Private consultants in the UK started using Proclarix in 2023.
Why does the NHS not use this test?
Proclarix is fairly new to the UK and therefore it is not yet included in the NICE guidelines, which are followed by the NHS. It is hoped that Proclarix, or a similar test, will be introduced into the NHS over the next couple of years.
